MAYNF Stock Mayne Pharma (MAYNF, $3.04) RSI Indicator left the oversold zone on September 11, 2025
at Tickeron.com
MAYNF's RSI Oscillator ascends from oversold territory
The RSI Indicator for MAYNF moved out of oversold territory on September 11, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 21 similar instances when the indicator left oversold territory. In of the 21 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 24, 2025. You may want to consider a long position or call options on MAYNF as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MAYNF just turned positive on September 23, 2025. Looking at past instances where MAYNF's MACD turned positive, the stock continued to rise in of 33 cases over the following month. The odds of a continued upward trend are .
MAYNF moved above its 50-day moving average on September 23, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MAYNF advanced for three days, in of 47 cases, the price rose further within the following month. The odds of a continued upward trend are .
MAYNF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Aroon Indicator for MAYNF entered a downward trend on September 10, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 81, placing this stock better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MAYNF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.116) is normal, around the industry mean (9.383). MAYNF has a moderately low P/E Ratio (0.000) as compared to the industry average of (23.333). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.768). MAYNF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.029). P/S Ratio (0.990) is also within normal values, averaging (3.394).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Advertisement
General Information
Industry PharmaceuticalsMajor